Therapeutic targeting in lung cancer for the treatment of lymph node metastasis: GRIK3.
Fuente:
Zenodo
Gespeichert in:
| 1. Verfasser: | |
|---|---|
| Format: | Recurso digital |
| Veröffentlicht: |
Zenodo
2025
|
| Online-Zugang: | |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| _version_ | 1866901162208264192 |
|---|---|
| author | Mamoor, Shahan |
| author_facet | Mamoor, Shahan |
| contents | <p>The high rate of brain metastasis in patients with non-small cell and small cell lung cancer demands discovery of novel therapeutic targets to treat lymph node metastasis which serves as an intermediate to the CNS (central nervous system) (1-5). We recently utilized whole transcriptome technologies to define the full complement of differentially expressed kinases and phosphatases in HER2+ breast cancer: in the primary tumor, and in metastasis to the CNS (6-8). Here we utilize whole transcriptome technologies (9, 10) to measure total transcription in the lymph node metastases of humans with small cell and non-small cell lung cancer. We describe here a therapeutic target that is up-regulated and differentially expressed in lymph node metastasis in humans with small cell and non-small cell lung cancer, GRIK3, as a candidate therapeutic target for the medical management of lymph node metastasis in human lung cancer. </p> |
| format | Recurso digital |
| id | zenodo_https___doi_org_10_5281_zenodo_14721434 |
| institution | Zenodo |
| language | |
| publishDate | 2025 |
| publisher | Zenodo |
| record_format | zenodo |
| spellingShingle | Therapeutic targeting in lung cancer for the treatment of lymph node metastasis: GRIK3. Mamoor, Shahan <p>The high rate of brain metastasis in patients with non-small cell and small cell lung cancer demands discovery of novel therapeutic targets to treat lymph node metastasis which serves as an intermediate to the CNS (central nervous system) (1-5). We recently utilized whole transcriptome technologies to define the full complement of differentially expressed kinases and phosphatases in HER2+ breast cancer: in the primary tumor, and in metastasis to the CNS (6-8). Here we utilize whole transcriptome technologies (9, 10) to measure total transcription in the lymph node metastases of humans with small cell and non-small cell lung cancer. We describe here a therapeutic target that is up-regulated and differentially expressed in lymph node metastasis in humans with small cell and non-small cell lung cancer, GRIK3, as a candidate therapeutic target for the medical management of lymph node metastasis in human lung cancer. </p> |
| title | Therapeutic targeting in lung cancer for the treatment of lymph node metastasis: GRIK3. |
| url | https://doi.org/10.5281/zenodo.14721434 |